" class="no-js "lang="en-US"> Jay LeCoque - Medtech Alert
Saturday, October 04, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Jay LeCoque

Jay LeCoque

About Jay LeCoque

Trajectory changing CEO of both private equity and publicly listed global life sciences companies. Successful track record of delivering substantial increases in shareholder value. Experienced in leading and building global teams for growth, turnarounds, start-ups, acquisitions and integrations.

Based wherever I am at the moment.

Related Story

Uncategorized

 Source BioScience Launches Sanger Sequencing Service in San Diego

Source BioScience Launches Sanger Sequencing Service in San Diego, CA to Support Life Science Researchers With Market-leading Genomic Services

August 23 2022

A leading provider of Genomic services in the UK and Ireland, Source BioScience (“Source”), a part […]